|
|
| Welcome to the Advancing RNA newsletter, delivering weekly insights on RNA therapy development. Based on your interest in the recent webinar Deciphering mRNA Immunogenicity: The What, Why, And How Of Early Assessment Of Human Immune Response Of Your Molecule Candidate (from our sister newsletter Outsourced Pharm), we thought you’d find Advancing RNA useful for addressing the analytical, formulation, manufacturing, outsourcing, and supply chain challenges you face in this rapidly evolving space. If not, you can unsubscribe at any time. |
|
|
|
| Clinical Research As A Delicate Ecosystem | Making the right outsourcing decision can significantly contribute to the success and growth of your program, providing essential support and resources that empower it to thrive in its objectives and endeavors. Trust that your program is in hands you can rely on, where integrity is paramount, and excellence is the standard. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Overall, there are four high-level best practices/mindsets I proposed during a recent presentation that I believe will be crucial for us to bring some talented RNA therapeutic role models to the forefront. But there is one best practice that I think is worth emphasizing more than the others. |
|
|
|
|
|
| Potent Immune Response With Vernal's LNP-mRNAs | Article | By Julia Sakamoto, Vernal Biosciences | As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality. |
|
|
|
|
|
FEATURED EDITORIALS CONTINUED... |
|
|
|
ReciBioPharm’s Melanie Cerullo shares where mRNA needs to “catch up” to its oligonucleotide “cousin” molecules and where regulatory differences may be emerging between modalities. |
|
|
|
By Priyanka Bhendale, Markets and Markets | New market research about the gene therapy market from Markets And Markets reveals insights into macro trends, delivery methods, therapeutic areas, and more. |
|
|
.png){kind=logo}
